Explore why Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams.

FDA drug alerts in infectious diseases, including new drug approvals, safety warnings, recalls, and changes in indications.

Note that some links may require registration or subscription. An Air India passenger plane bound for London with more than ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental ...

U.S. Health Secretary Robert F. Kennedy Jr. has named eight new members to the Centers for Disease Control and Preventions ...

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...

(NVAX) on Wednesday said that its COVID-19-Influenza combination and stand-alone Influenza vaccine candidates demonstrated a ...

Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...

The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...

Novavax (NVAX) stock gains as the company reports promising Phase 3 trial results for its COVID-19-Influenza combo vaccine and stand-alone flu shot. Read more here.

The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.